FSHD Radio: Hot off the Press – Mel Hayes of Fulcrum Therapeutics on the REACH Trial

Thursday, September 28th 

14:00 PM CET | 13:00 PM UK | 8:00 AM ET | 7:00 AM CT | 6:00 AM MT | 5:00 AM PT

Earlier this month, Fulcrum Therapeutics confirmed the completion of patient enrollment in the Phase 3 REACH clinical trial for losmapimod (read about the exciting news here), a potential groundbreaking therapy for FSHD. For this episode of Hot off the Press, Mel Hayes, Chief Operating Officer of Fulcrum, will sit down with Tim to discuss what this milestone means, answer questions about the REACH Trial, and fill us in on the latest from Project Mercury. 

On the 4^th Thursday of every month, look for a new episode of FSHD Radio: Hot off the Press. Each month we will bring you a short-form show that will bring you the latest and greatest from the FSHD Society, including research updates, upcoming events, and important developments to keep you updated on all things FSHD.

A new video podcast is released the 4th Thursday of every month on YouTube and Facebook. Share your thoughts, or post questions in the comments section. You can also listen to the episode on your favorite podcast app. Subscribe on YouTube or your podcast app to make sure you never miss an episode!